Status:
COMPLETED
A Study of ABT-751 in Patients With Colorectal Cancer
Lead Sponsor:
Abbott
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Colorectal cancer.
- Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney, and liver function.
- Exclusion Criteria
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- Prior radiation therapy.
- CNS metastasis.
Exclusion
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00073138
Start Date
August 1 2003
End Date
February 1 2005
Last Update
November 29 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90089
2
Cancer Institute Medical Group
Santa Monica, California, United States, 90095-3961
3
Northwestern University
Chicago, Illinois, United States, 60611-5933
4
University of Chicago Medical Center
Chicago, Illinois, United States, 60637